Glycopyrronium tosylate

Glycopyrronium tosylate

Clinical data
Trade names	Qbrexza, Rapifort
Other names	Glycopyrronium tosilate hydrate (JAN JP)
AHFS/Drugs.com	Monograph
License data	US  DailyMed:  Glycopyrronium
Routes of administration	Topical
Drug class	Muscarinic antagonist
ATC code	D11AA01 ( WHO )
Legal status
Legal status	US: ℞-only [1] In general: ℞ (Prescription only)
Identifiers
CAS Number	1624259-25-1
PubChem CID	121225724
DrugBank	DBSALT002800
ChemSpider	58902513
UNII	1PVF6JLU7B
KEGG	D10939
ChEMBL	ChEMBL3707243
Chemical and physical data
3D model (JSmol)	Interactive image
SMILES O.Cc1ccc(cc1)S(=O)(=O)[O-].C[N+]2(C)CC[C@@H](C2)OC(=O)[C@@](O)(C3CCCC3)c4ccccc4
InChI InChI=1S/C19H28NO3.C7H8O3S.H2O/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;1-6-2-4-7(5-3-6)11(8,9)10;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;2-5H,1H3,(H,8,9,10);1H2/q+1;;/p-1/t17-,19-;;/m0../s1 Key:UOWOLENSDISMPG-FFUVTKDNSA-M

Glycopyrronium tosylate, sold under the brand name Qbrexza among others, is a medication used for the treatment of primary axillary hyperhidrosis. ^{[1] [2] [3]}

It was approved for medical use in the United States in June 2018, ^[4] and in Japan in January 2022. ^[5]

References

1. "Qbrexza- glycopyrronium cloth". DailyMed. 17 January 2022. Retrieved 2 November 2022.
2. Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, Tyring SK (March 2019). "Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis". Skin Therapy Letter. 24 (2): 1–3. PMID   30970203.
3. Lamb YN (November 2019). "Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use". Clinical Drug Investigation. 39 (11): 1141–1147. doi:10.1007/s40261-019-00853-x. PMC   6877702 . PMID   31571127.
4. "Drug Approval Package: Qbrexza (glycopyrronium)". U.S. Food and Drug Administration (FDA). 20 November 2018. Archived from the original on 11 April 2021. Retrieved 1 November 2022.
5. "Maruho Launches Primary Axillary Hyperhidrosis Treatment". Maruho. 23 May 2022. Retrieved 2 November 2022.